Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Cannabis Law Report

DECEMBER 1, 2019

A young girl with a drug-resistant form of epilepsy is believed to be the first and only patient in Singapore who has been given approval to use cannabis-derived medication. The move follows approvals by lawmakers in the United States to use the medication to treat rare kinds of childhood epilepsy in that country.

Epilepsy 59

Epilepsy Cannabinoids Therapy Treatment 59

Canna Law Blog

DECEMBER 16, 2021

Psilocybin therapy is a breakthrough avenue for providing people with treatment for these ailments. Data from the RAND Corporation show that 8,000 New York veterans from the Wars in Iraq and Afghanistan suffer from PTSD. The FDA recognizes psilocybin therapy as substantially better than present treatment options.

Legislation 96

Legislation Treatment Therapy Conditions 96

Cannabis Law Report

DECEMBER 11, 2021

The clinic established the UK Medical Cannabis Registry to offer patients medical cannabis products at a reduced price while collecting and analysing clinical data from real-world evidence “to expand our understanding of medical cannabis in the UK”. The Sapphire Access Scheme will be open to an additional 2,000 patients in the UK.

Access 52

Access Patients Chronic Pain Treatment 52

The Cannigma

JULY 17, 2022

You don’t need a medical condition or a paid subscription – the ROC serves curious consumers, medical professionals, and anyone else who is looking to better their life through cannabinoid therapies. The advice and suggestions are based on data, including the results from ROC’s own cannabis research registry.

Advocacy 120

Advocacy Education Events Epilepsy 120

The Joint Blog

JULY 17, 2020

According to a new study published in the journal Seminars in Pediatric Neurology, marijuana-based products are associated with improvements in the symptoms of autistic patients who have self-injurious behaviors and co-morbid epilepsy. Those diagnosed with both ASD and epilepsy saw a 91% seizure control improvement.

Epilepsy 47

Epilepsy Research and Development Marijuana Treatment 47

Veriheal

APRIL 11, 2022

We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds. This means that U.S. We could potentially develop north of 11,000 drugs that are cannabinoid-based. Absolutely.”

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

JULY 25, 2022

Cancer, including remission therapy. Although a lot of research is being conducted on the subject, no conclusive medical data has been provided to the medical community. Some of the conditions that qualify for receiving medical marijuana treatment in Pennsylvania include, but are not limited to: Muscle spasticity. Anxiety disorders.

Legalization 52

Legalization Marijuana Epilepsy Sativa 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

SEPTEMBER 13, 2021

Positive data from this important study would significantly advance MYMD-1’s potential to become a blockbuster drug for inflammation and aging.”. Unlike other therapies, MYMD-1 is designed to selectively block TNF-? The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Food and Drug Administration clearance of its Investigational New Drug (IND) application for the Phase 2 trial of MYMD-1 as a therapy for delaying aging and prolonging healthy lifespan. a driver of chronic inflammation.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Joint Blog

FEBRUARY 24, 2021

Cannabis and CBD oils have often been used to reduce the effects of epilepsy and several other neurological issues, so why not Parkinson’s? Volume 33 of Complementary Therapies in Medicine states that 40% of patients with Parkinson’s Disease or Multiple Sclerosis are already self-medicating with cannabis.

Treatment 55

Treatment Clinical Trials Collective Patients 55

CannaMD

AUGUST 19, 2020

Our initial data suggest that some C. Although various possibilities are being explored, at the time of publication, scientific literature does not support the use of medical cannabis as a therapy for the prevention and/or treatment of COVID-19. Writing that “the extracts of our most successful and novel high-CBD C.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

AUGUST 5, 2019

The study, conducted the company’s digital marketing arm, LOCALiQ, combined survey responses with mobile data to paint a picture of cannabis consumers in legal states. USA Today Report: Cannabis Consumers Reduce Use of Pills, Booze. . Read more. . More Kroger Co. Stores To Carry CBD Products. . Charlotte’s Web Holdings Inc.

Law 40

Law Decriminalization Hemp Legislation 40

The Joint Blog

JANUARY 12, 2020

“The growth is more rapid than I’ve seen for any product in 20 years in this business,” said Bill Bookout, president of the National Animal Supplement Council, an industry group whose member companies agree to testing and data-gathering requirements. There’s a gold rush going on now.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Veriheal

JULY 5, 2021

The self-reported data was logged between June 6, 2016, and July 8, 2019. The UNM researchers noted that, since nausea is just one symptom, CBD may be a better option for relieving the symptoms associated with other types of medical conditions, such as epilepsy and chronic pain. Food poisoning. Emotional distress. Motion sickness.

THC 52

THC CBD Treatment Cannabinoids 52

Greencamp

AUGUST 16, 2018

The CBD cannabinoid is proven to be an exceptional seizure-controlling agent for epilepsy patients, and also shows great promise for treating Parkinson’s , Alzheimer’s and Multiple Sclerosis. Marijuana and Epilepsy: Here’s How Cannabis Stops Seizures (12 Studies). Exploring the available research on ALS and cannabinoids.

Strains 94

Strains Cannabinoids Research and Development Indica 94

Veriheal

MAY 31, 2022

According to data released by the Centers for Disease Control and Prevention , there were an estimated 2,620 opioid overdose deaths in Texas between Aug. According to Dr. Haider Warraich , interdisciplinary pain rehabilitation programs that combine therapy with medication are considered the gold standard of chronic pain care.

Programs 52

Programs Chronic Pain Treatment Conditions 52

The Joint Blog

NOVEMBER 22, 2021

If you’re looking to improve your health, focus on a specific ailment, improving the appearance of the skin, accelerate effective therapies and alternatives then it’s something to consider.

CBD 26

CBD Epilepsy Food Hemp 26

Cannabis Law Report

JANUARY 20, 2022

Merger also to support nationwide expansion of Eleusis’s subsidiary Andala, which manages in-network drug therapy clinics targeting the “last mile” challenge of psychedelic care delivery to address a potential $7 billion U.S. Currently, its managed clinics provide access to FDA-approved drug therapies like SPRAVATO (esketamine).

Therapy 52

Therapy Research and Development Business Access 52

Greenspoon Marder Cannabis Law Group Blog

APRIL 2, 2019

For example, we’re seeking comments, data and information on a variety of topics including: what levels of cannabis and cannabis-derived compounds cause safety concerns; how the mode of delivery (e.g., Selling unapproved products with unsubstantiated therapeutic claims can put patients and consumers at risk.

CBD 40

CBD Research and Development Safety Therapy 40

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. As more people take cannabinoids for approved nausea, vomiting, and approved uses, the data on the effects that they have on cancer can supplement research and clinical trials.

Treatment 64

Treatment Clinical Trials Research and Development Cannabinoids 64

Puff Puff Post

JANUARY 1, 2020

Sativex is a cannabinoid medication prescribed to cancer patients and individuals suffering from epilepsy and other muscle disorders. As more people take cannabinoids for approved nausea, vomiting, and approved uses, the data on the effects that they have on cancer can supplement research and clinical trials.

Treatment 40

Treatment Clinical Trials Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 26, 2021

Unlike other therapies, MYMD-1 has been shown to selectively block TNF-? In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. 1 Data published by Research and Markets, March 2018. a driver of chronic inflammation.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 12, 2021

For several millennia, humans have used cannabinoids for pain, epilepsy, gastrointestinal disorders, and even infections. We need to see data demonstrating the differences in oral bioavailability among these different compounds.”. Cats are more challenging. I am excited about CBD,” she said. “I I think it’s a very safe compound.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

Cannabis Law Report

MARCH 3, 2020

We strive to make a firsthand connection with every patient or caretaker to provide them with reliable and effective cannabis based therapies. Smullen’s motivation: His daughter suffered from epilepsy and had her first grand mal seizure when she was 2… she could have been helped by medical marijuana. FLORIDA FOCUS.

Dispensary 64

Dispensary Patients Cannabis Wellness and Beauty 64

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy. Palliative care indications.

Research and Development 52

Research and Development Medicine Access Media 52

CannaTech

SEPTEMBER 23, 2019

NICE develop evidence-based guidelines on a wide range of health-related topics, including integrating novel and emerging therapies. In the case of cannabis, these interests were absent, constituting an additional reason for limited clinical trial data on cannabis.

Patients 79

Patients Policy Clinical Trials Research and Development 79

Green Relief

MAY 13, 2018

It is the most commonly identified cause of epilepsy among adults. government-sponsored scientific research – and to extensive anecdotal accounts from medical marijuana patients – which highlight the potential of cannabinoid-based therapies for TBI. Hypothermia is typically the go-to therapy for treating newborn infants after a stroke.

THC 64

THC CBD Cannabinoids Research and Development 64

The Cannigma

SEPTEMBER 13, 2021

Also in 2020, Israel surpassed Germany as the world’s largest importer of medical cannabis flower, according to data from Israel’s online Cannabis Magazine. The Israeli government formally legalized medical marijuana in 1999, and by 2020 the number of registered patients reached a record high of over 70,000.

Legalization 97

Legalization Decriminalization Patients Cannabis 97

Green Relief

MAY 12, 2018

It is the most commonly identified cause of epilepsy among adults. government-sponsored scientific research – and to extensive anecdotal accounts from medical marijuana patients – which highlight the potential of cannabinoid-based therapies for TBI. Hypothermia is typically the go-to therapy for treating newborn infants after a stroke.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

OCTOBER 26, 2019

The TGA does not evaluate any data relating to the trial. Data exclusivityThe TG Act provides a data exclusivity period of five years in relation to therapeutic goods containing a new active component (that is, an active substance that has not previously been a component of a product entered in the ARTG).

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Healer

JUNE 28, 2019

Patients with advanced cancer who have pain that responds poorly to opioid therapy pose a clinical challenge. Adopted Name for Sativex , which does not yet have an INN), a novel cannabinoid formulation, is undergoing investigation as add-on therapy for this population. Nabiximols (Nabiximols is the U.S. Abstract: Medical Study .

Cannabinoids 52

Cannabinoids THC Therapy Patients 52

Cannabis Law Report

JULY 12, 2019

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. An Israeli study of cannabis versus epilepsy, however, used natural extracts with a ratio of 20:1 CBD:THC. Lancet Neurol Dec 23 2015.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Puff Puff Post

DECEMBER 28, 2018

We go deep into what this might mean for the future of therapy for Autism Spectrum Disorders (ASD), and how we might see the use of CBD oil for autism. An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Success rates of up to 80% have been observed for CBD related autism therapy.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

SEPTEMBER 1, 2022

exas’ leading medical cannabis provider is highlighting the medicine’s efficacy in pain management therapies during Pain Awareness Month. “The data is clear. “Hardly a week goes by without seeing a headline about the staggering amount of fentanyl crossing the border or increase in opioid overdose deaths.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52

Cannabis Law Report

AUGUST 31, 2022

Texas’ leading medical cannabis provider is highlighting the medicine’s efficacy in pain management therapies during Pain Awareness Month. The data is clear. In particular, the Baselice & Associates, Inc.

Chronic Pain 52

Chronic Pain Programs Patients Conditions 52